Northern Trust
ARQT icon

Northern Trust’s Arcutis Biotherapeutics ARQT Stock Holding History

Northern Trust’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.8M Buy
1,058,575
+82,063
+8% +$1.91M ﹤0.01% 1600
2026
Q1 		$23M Buy
976,512
+21,277
+2% +$543K ﹤0.01% 1587
2025
Q4 		$27.7M Buy
955,235
+15,033
+2% +$385K ﹤0.01% 1459
2025
Q3 		$17.7M Buy
940,202
+11,514
+1% +$182K ﹤0.01% 1769
2025
Q2 		$13M Sell
928,688
-47,382
-5% -$664K ﹤0.01% 1914
2025
Q1 		$15.3M Sell
976,070
-14,986
-2% -$211K ﹤0.01% 1792
2024
Q4 		$13.8M Buy
991,056
+54,541
+6% +$598K ﹤0.01% 1938
2024
Q3 		$8.71M Buy
936,515
+184,665
+25% +$1.82M ﹤0.01% 2148
2024
Q2 		$6.99M Buy
751,850
+2,905
+0.4% +$26.3K ﹤0.01% 2206
2024
Q1 		$7.42M Buy
748,945
+18,201
+2% +$136K ﹤0.01% 2235
2023
Q4 		$2.36M Buy
730,744
+247,245
+51% +$672K ﹤0.01% 2902
2023
Q3 		$2.57M Buy
483,499
+17,846
+4% +$152K ﹤0.01% 2802
2023
Q2 		$4.44M Buy
465,653
+78,792
+20% +$875K ﹤0.01% 2570
2023
Q1 		$4.26M Buy
386,861
+2,009
+0.5% +$29.1K ﹤0.01% 2562
2022
Q4 		$5.7M Buy
384,852
+11,151
+3% +$195K ﹤0.01% 2404
2022
Q3 		$7.14M Buy
373,701
+58,643
+19% +$1.33M ﹤0.01% 2228
2022
Q2 		$6.71M Buy
315,058
+56,121
+22% +$1.15M ﹤0.01% 2312
2022
Q1 		$4.99M Sell
258,937
-11,016
-4% -$186K ﹤0.01% 2589
2021
Q4 		$5.6M Sell
269,953
-566
-0.2% -$11.3K ﹤0.01% 2619
2021
Q3 		$6.46M Sell
270,519
-19,584
-7% -$447K ﹤0.01% 2576
2021
Q2 		$7.92M Buy
290,103
+23,285
+9% +$656K ﹤0.01% 2532
2021
Q1 		$7.72M Buy
266,818
+26,563
+11% +$829K ﹤0.01% 2468
2020
Q4 		$6.76M Buy
240,255
+29,987
+14% +$734K ﹤0.01% 2495
2020
Q3 		$6.16M Buy
210,268
+81,938
+64% +$2.19M ﹤0.01% 2404
2020
Q2 		$3.88M Buy
128,330
+19,871
+18% +$574K ﹤0.01% 2667
2020
Q1 		$3.23M Buy
+108,459
New +$2.91M ﹤0.01% 2566

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Northern Trust's ARQT Position: Q2 2026 in Review

Northern Trust increased its Arcutis Biotherapeutics (ARQT) stake by 8.4% in Q2 2026, buying an estimated $1.91M and bringing the position to 1,058,575 shares worth $27.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1600.

Northern Trust first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Northern Trust held 1,058,575 shares of Arcutis Biotherapeutics worth $27.8M as of Q2 2026.
  • Northern Trust bought 82,063 Arcutis Biotherapeutics shares in Q2 2026, an estimated $1.91M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #1600 holding.
  • Northern Trust first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.